- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 | 3 | Seeking Alpha | ||
| 15.05. | Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock | 2 | Investing.com | ||
| 14.05. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 525 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 05.05. | Piper Sandler sets $6 target for Acrivon stock, rates it Overweight | 1 | Investing.com | ||
| 25.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 07.04. | Acrivon appoints new chief medical officer to advance cancer trials | 1 | Investing.com | ||
| 07.04. | Acrivon ernennt neuen medizinischen Leiter zur Förderung von Krebsstudien | 2 | Investing.com Deutsch | ||
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 96 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 07.04. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | H.C. Wainwright maintains Acrivon stock Buy rating, $19 target | 2 | Investing.com | ||
| 28.03. | Acrivon Therapeutics reports Q4 results | 6 | Seeking Alpha | ||
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 137 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright | 7 | Investing.com | ||
| 26.03. | Cantor Fitzgerald maintains Overweight on Acrivon stock | 3 | Investing.com | ||
| 26.03. | Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial | 8 | FierceBiotech | ||
| 26.03. | JMP maintains Acrivon stock with $17 target following update | 3 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,00 | -0,22 % | BioNTech, Moderna und Co im Fokus: Kennedy greift durch | Nächster Paukenschlag in den USA: Gesundheitsminister Robert F. Kennedy Jr. hat alle Mitglieder eines Gremiums (ACIP) von Impfexperten der US- Seuchenbehörde CDC entlassen. Das geht aus einer Mitteilung... ► Artikel lesen | |
| CUREVAC | 4,848 | +0,46 % | Mega-Deal in der Biotech-Branche: BioNTech greift nach CureVac! | In einer wegweisenden Branchenfusion übernimmt BioNTech SE (Nasdaq: BNTX), Pionier der mRNA-Technologie und bekannt durch den COVID-19-Impfstoff, das deutsche Biotech-Unternehmen CureVac N.V. (Nasdaq:... ► Artikel lesen | |
| AMGEN | 255,25 | -0,14 % | How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks? | ||
| NOVAVAX | 6,000 | -0,07 % | Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase... ► Artikel lesen | |
| BIOGEN | 113,15 | 0,00 % | UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal | WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,655 | +0,35 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,016 | -2,45 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,834 | -1,56 % | Colombia approves BioCryst's oral HAE treatment ORLADEYO | ||
| TEMPUS AI | 61,52 | -0,36 % | Tempus AI kooperiert mit Northwestern zur Förderung der Alzheimer-Forschung | ||
| SAREPTA THERAPEUTICS | 31,460 | +0,38 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,260 | +0,32 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,048 | +0,46 % | Pacific Biosciences bei Goldman Sachs: Sequenzierungsinnovation und Wachstum | ||
| EXELIXIS | 35,600 | -1,11 % | Exelixis stock maintains buy rating at H.C. Wainwright on promising data | ||
| VAXART | 0,615 | +0,24 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,12 % bei einem Aktienkurs von 1,205 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.